CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: TMEM192 (ImmuneEditome ID:201931)

1. Gene summary of enriched editing regions for TMEM192

check button Gene summary
Gene informationGene symbol

TMEM192

Gene ID

201931

GeneSynonyms-
GeneCytomap

4q32.3

GeneTypeprotein-coding
GeneDescriptiontransmembrane protein 192
GeneModificationdate20230329
UniprotIDQ8IY95;D6RAZ6
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr4:165071311-165072399:-ENST00000306480.9ENSG00000170088.12TMEM192UTR3AluSz,AluSg,L2a,AluSxchr4:165071311-165072399:-.alignment
chr4:165074503-165079060:-ENST00000306480.9ENSG00000170088.12TMEM192UTR3AluSp,(ATACAT)n,AluSz6,FLAM_C,AluSx,L1ME3G,AluSc,L2,AluYh3,AluSg4,AluSgchr4:165074503-165079060:-.alignment
chr4:165074503-165079060:-ENST00000506087.4ENSG00000170088.12TMEM192UTR3AluSp,(ATACAT)n,AluSz6,FLAM_C,AluSx,L1ME3G,AluSc,L2,AluYh3,AluSg4,AluSgchr4:165074503-165079060:-.alignment


Top

2. Tumor-specific enriched editing regions for TMEM192


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr4:165074503-165079060:-BRCAEER1.6393e-35image
ENSG00000170088.12,TMEM192BRCAEAG1.1257e-35image
chr4:165074503-165079060:-COADEER1.6336e-02image
ENSG00000170088.12,TMEM192COADEAG1.6346e-02image
chr4:165074503-165079060:-HNSCEER3.4480e-11image
ENSG00000170088.12,TMEM192HNSCEAG3.4219e-11image
chr4:165074503-165079060:-KICHEER3.2810e-10image
ENSG00000170088.12,TMEM192KICHEAG5.7338e-10image
chr4:165074503-165079060:-KIRCEER6.2649e-13image
ENSG00000170088.12,TMEM192KIRCEAG5.7118e-13image
chr4:165074503-165079060:-KIRPEER8.1167e-04image
ENSG00000170088.12,TMEM192KIRPEAG6.7219e-04image
chr4:165074503-165079060:-LIHCEER2.7584e-03image
ENSG00000170088.12,TMEM192LIHCEAG2.6274e-03image
chr4:165074503-165079060:-LUADEER1.9983e-02image
ENSG00000170088.12,TMEM192LUADEAG1.9884e-02image
chr4:165074503-165079060:-LUSCEER6.8040e-13image
ENSG00000170088.12,TMEM192LUSCEAG6.7961e-13image
chr4:165074503-165079060:-THCAEER4.4931e-05image
ENSG00000170088.12,TMEM192THCAEAG4.9203e-05image
chr4:165074503-165079060:-UCECEER1.8316e-16image
ENSG00000170088.12,TMEM192UCECEAG1.7581e-16image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr4:165074503-165079060:-KIRCPathEER8.3396e-086.2547e-090.2485image
ENSG00000170088.12,TMEM192KIRCPathEAG8.4394e-086.5160e-090.2482image
chr4:165074503-165079060:-KIRPPathEER3.5515e-041.2830e-040.2357image
ENSG00000170088.12,TMEM192KIRPPathEAG4.8741e-041.4255e-040.2342image
chr4:165074503-165079060:-PAADPathEER4.2325e-021.1199e-020.1988image
ENSG00000170088.12,TMEM192PAADPathEAG4.2325e-021.1199e-020.1988image
chr4:165074503-165079060:-THCAPathEER3.1542e-065.8178e-040.1529image
ENSG00000170088.12,TMEM192THCAPathEAG3.5950e-065.9601e-040.1526image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for TMEM192


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr4:165074503-165079060:-LIHCEERENSG00000170088,TMEM192-0.43338.2418e-155.4136e-17-0.4164imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_BILE_ACID_METABOLISM
chr4:165074503-165079060:-COADEERENSG00000170088,TMEM192-0.53434.5452e-154.7833e-18-0.5043imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAT_cells_CD8GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr4:165074503-165079060:-UCECEERENSG00000143256,PFDN20.38894.4592e-041.8675e-090.4368imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_DN
chr4:165074503-165079060:-UCECEERENSG00000163156,SCNM10.38414.6187e-044.7108e-090.4269imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAT_cells_CD4_memory_restingGSVA_HALLMARK_ANDROGEN_RESPONSE
chr4:165074503-165079060:-UCECEERENSG00000231563,RP11-245P10.40.29461.2712e-021.4801e-100.4626imageNEIF4A3;ELAVL1;FUS;NOP56NAB_cells_memoryGSVA_HALLMARK_MTORC1_SIGNALING
chr4:165074503-165079060:-KIRPEERENSG00000161888,SPC240.32831.9319e-071.8386e-120.4002imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAT_cells_gamma_deltaGSVA_HALLMARK_E2F_TARGETS
chr4:165074503-165079060:-KIRPEERENSG00000233461,RP11-295G20.20.34613.0882e-073.0982e-140.4284imageNEIF4A3;ELAVL1;IGF2BP2;NOP56NAT_cells_CD4_memory_activatedGSVA_HALLMARK_MYC_TARGETS_V2
chr4:165074503-165079060:-KIRPEERENSG00000077152,UBE2T0.31369.1273e-073.2554e-150.4428imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAMacrophages_M1GSVA_HALLMARK_E2F_TARGETS
chr4:165074503-165079060:-KIRPEERENSG00000164611,PTTG10.27839.5075e-064.2358e-280.5882imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAT_cells_gamma_deltaGSVA_HALLMARK_E2F_TARGETS
chr4:165074503-165079060:-KIRPEERENSG00000117399,CDC200.24332.0246e-046.0002e-160.4533imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAMacrophages_M1GSVA_HALLMARK_E2F_TARGETS
chr4:165074503-165079060:-LIHCEERENSG00000170088,TMEM192-0.43338.2418e-155.4136e-17-0.4164imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_BILE_ACID_METABOLISM
chr4:165074503-165079060:-COADEERENSG00000170088,TMEM192-0.53434.5452e-154.7833e-18-0.5043imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAT_cells_CD8GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr4:165074503-165079060:-UCECEERENSG00000143256,PFDN20.38894.4592e-041.8675e-090.4368imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_DN
chr4:165074503-165079060:-UCECEERENSG00000163156,SCNM10.38414.6187e-044.7108e-090.4269imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAT_cells_CD4_memory_restingGSVA_HALLMARK_ANDROGEN_RESPONSE
chr4:165074503-165079060:-UCECEERENSG00000231563,RP11-245P10.40.29461.2712e-021.4801e-100.4626imageNEIF4A3;ELAVL1;FUS;NOP56NAB_cells_memoryGSVA_HALLMARK_MTORC1_SIGNALING
chr4:165074503-165079060:-KIRPEERENSG00000161888,SPC240.32831.9319e-071.8386e-120.4002imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAT_cells_gamma_deltaGSVA_HALLMARK_E2F_TARGETS
chr4:165074503-165079060:-KIRPEERENSG00000233461,RP11-295G20.20.34613.0882e-073.0982e-140.4284imageNEIF4A3;ELAVL1;IGF2BP2;NOP56NAT_cells_CD4_memory_activatedGSVA_HALLMARK_MYC_TARGETS_V2
chr4:165074503-165079060:-KIRPEERENSG00000077152,UBE2T0.31369.1273e-073.2554e-150.4428imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAMacrophages_M1GSVA_HALLMARK_E2F_TARGETS
chr4:165074503-165079060:-KIRPEERENSG00000164611,PTTG10.27839.5075e-064.2358e-280.5882imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAT_cells_gamma_deltaGSVA_HALLMARK_E2F_TARGETS
chr4:165074503-165079060:-KIRPEERENSG00000117399,CDC200.24332.0246e-046.0002e-160.4533imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAMacrophages_M1GSVA_HALLMARK_E2F_TARGETS

More results



Top

4. Enriched editing regions and immune related splicing for TMEM192


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000170088.12,TMEM192
DLBCEAGIRENSG00000156976.10chr3186787775:186787882:186789124:186789140-0.69583.5041e-023.2162e-04-0.4975imageNADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;SAFB2;SF3B4;SLTM;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDF1;YWHAG;ZC3H7B;ZNF184NAMacrophages_M2GSVA_HALLMARK_MITOTIC_SPINDLE
chr4:165074503-165079060:-
DLBCEERIRENSG00000156976.10chr3186787775:186787882:186789124:186789140-0.69583.9494e-023.2162e-04-0.4975imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAMacrophages_M2GSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000170088.12,TMEM192
KIRPEAGMEXENSG00000126456.11chr1949660712:49660828:49661947:49662021:49662184:49662328:49662424:496626170.31413.9598e-056.8416e-130.4072imageNADAR;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDF1;YWHAG;ZNF184IRF3T_cells_gamma_deltaGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000170088.12,TMEM192
KIRPEAGA3ENSG00000164054.11chr348469360:48469410:48467875:48468217:48467875:484691860.21211.8691e-021.4007e-120.4021imageNADAR;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RC3H1;RNF219;SAFB2;SF3B4;SLTM;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDF1;YWHAG;ZNF184SHISA5GSVA_HALLMARK_HEME_METABOLISM
chr4:165074503-165079060:-
KIRPEERMEXENSG00000073578.12chr5240443:240476:250991:251043:254392:254506:256333:256682-0.33121.2015e-053.5719e-16-0.4564imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000170088.12,TMEM192
KIRPEAGMEXENSG00000089280.14chr1631190274:31190398:31190741:31190788:31190962:31191110:31191398:31191558-0.34333.1358e-064.6300e-16-0.4548imageNADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3B4;SLTM;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDF1;YWHAG;ZC3H7B;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr4:165074503-165079060:-
KIRPEERMEXENSG00000073578.12chr5240443:240476:250991:251043:254357:254506:256333:256682-0.32841.4800e-053.2850e-16-0.4569imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr4:165074503-165079060:-
KIRPEERA5ENSG00000111653.15chr126652661:6652767:6652944:6653050:6652935:66530500.23001.0919e-021.2126e-120.4038imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1ING4T_cells_CD4_memory_activatedGSVA_HALLMARK_APICAL_SURFACE
chr4:165074503-165079060:-
KIRPEERMEXENSG00000137824.11chr1540737964:40738042:40738500:40738576:40745119:40745259:40751425:407515690.23071.1001e-021.0325e-120.4043imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr4:165074503-165079060:-
KIRPEERMEXENSG00000111481.5chr1254325150:54325181:54340546:54340615:54343224:54343316:54345459:54345475-0.22821.2674e-021.2656e-12-0.4029imageNEIF4A3;ELAVL1;FUS;IGF2BP2;NOP56;PTBP1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION

More results



Top

5. Enriched editing regions and immune infiltration for TMEM192


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr4:165074503-165079060:-ACCEERNK_cells_resting4.8027e-020.2276image
ENSG00000170088.12,TMEM192ACCEAGNK_cells_resting4.2957e-020.2328image
chr4:165074503-165079060:-BLCAEERT_cells_CD4_memory_activated1.8686e-040.1918image
ENSG00000170088.12,TMEM192BLCAEAGT_cells_CD4_memory_activated1.8823e-040.1917image
chr4:165074503-165079060:-BRCAEERT_cells_regulatory_(Tregs)6.0153e-070.1525image
ENSG00000170088.12,TMEM192BRCAEAGT_cells_regulatory_(Tregs)4.9560e-070.1536image
chr4:165074503-165079060:-CESCEERMacrophages_M21.3742e-02-0.1521image
ENSG00000170088.12,TMEM192CESCEAGMacrophages_M21.3742e-02-0.1521image
chr4:165074503-165079060:-COADEERMonocytes2.1255e-02-0.1434image
ENSG00000170088.12,TMEM192COADEAGMonocytes2.1255e-02-0.1434image
chr4:165074503-165079060:-DLBCEERDendritic_cells_activated2.3555e-02-0.3264image
ENSG00000170088.12,TMEM192DLBCEAGDendritic_cells_activated2.3555e-02-0.3264image
chr4:165071311-165072399:-ESCAEERT_cells_CD83.7328e-02-0.4682image
chr4:165074503-165079060:-ESCAEERT_cells_CD4_memory_resting5.7602e-04-0.2726image
ENSG00000170088.12,TMEM192ESCAEAGT_cells_CD4_memory_resting7.4485e-04-0.2672image
chr4:165074503-165079060:-GBMEERDendritic_cells_activated4.0569e-020.1631image
ENSG00000170088.12,TMEM192GBMEAGDendritic_cells_activated3.8881e-020.1645image
chr4:165074503-165079060:-HNSCEERT_cells_CD4_memory_resting1.2012e-02-0.1250image
ENSG00000170088.12,TMEM192HNSCEAGT_cells_CD4_memory_resting1.1982e-02-0.1251image
chr4:165074503-165079060:-KICHEERB_cells_naive1.3022e-02-0.3065image
ENSG00000170088.12,TMEM192KICHEAGB_cells_naive1.3009e-02-0.3065image
chr4:165074503-165079060:-KIRCEERT_cells_CD4_memory_activated4.3309e-070.2545image
ENSG00000170088.12,TMEM192KIRCEAGT_cells_CD4_memory_activated4.5260e-070.2541image
chr4:165074503-165079060:-KIRPEERMacrophages_M14.4087e-050.2387image
ENSG00000170088.12,TMEM192KIRPEAGMacrophages_M14.2795e-050.2391image
chr4:165074503-165079060:-LAMLEERMacrophages_M21.3176e-02-0.2796image
ENSG00000170088.12,TMEM192LAMLEAGMacrophages_M23.4205e-02-0.2401image
chr4:165074503-165079060:-LGGEERT_cells_CD4_naive2.1697e-02-0.1004image
ENSG00000170088.12,TMEM192LGGEAGT_cells_CD4_naive2.1628e-02-0.1004image
chr4:165074503-165079060:-LIHCEERT_cells_regulatory_(Tregs)2.9474e-050.2151image
ENSG00000170088.12,TMEM192LIHCEAGT_cells_regulatory_(Tregs)3.0503e-050.2147image
chr4:165074503-165079060:-LUADEERT_cells_regulatory_(Tregs)4.6391e-050.1840image
ENSG00000170088.12,TMEM192LUADEAGT_cells_regulatory_(Tregs)4.5940e-050.1841image
chr4:165074503-165079060:-LUSCEERDendritic_cells_resting2.0390e-02-0.1171image
ENSG00000170088.12,TMEM192LUSCEAGDendritic_cells_resting2.0390e-02-0.1171image
chr4:165074503-165079060:-MESOEERMast_cells_resting2.2820e-02-0.2527image
ENSG00000170088.12,TMEM192MESOEAGMast_cells_resting2.2820e-02-0.2527image
chr4:165074503-165079060:-OVEERT_cells_follicular_helper2.0900e-020.1378image
ENSG00000170088.12,TMEM192OVEAGT_cells_follicular_helper2.5167e-020.1336image
chr4:165074503-165079060:-PCPGEERB_cells_memory7.6654e-030.1965image
ENSG00000170088.12,TMEM192PCPGEAGB_cells_memory7.6458e-030.1966image
chr4:165071311-165072399:-PRADEERNK_cells_activated5.8493e-040.6089image
chr4:165074503-165079060:-PRADEERT_cells_regulatory_(Tregs)1.2513e-080.2514image
ENSG00000170088.12,TMEM192PRADEAGT_cells_regulatory_(Tregs)1.3344e-080.2509image
chr4:165074503-165079060:-SARCEERT_cells_gamma_delta5.0961e-050.2726image
ENSG00000170088.12,TMEM192SARCEAGT_cells_gamma_delta5.0961e-050.2726image
chr4:165074503-165079060:-SKCMEERT_cells_CD83.9420e-090.2695image
ENSG00000170088.12,TMEM192SKCMEAGT_cells_CD84.4890e-090.2686image
chr4:165074503-165079060:-STADEERT_cells_gamma_delta8.4591e-030.1437image
ENSG00000170088.12,TMEM192STADEAGT_cells_gamma_delta7.9846e-030.1447image
chr4:165074503-165079060:-TGCTEERNeutrophils8.6357e-040.3091image
ENSG00000170088.12,TMEM192TGCTEAGNeutrophils8.6357e-040.3091image
chr4:165071311-165072399:-THCAEERDendritic_cells_resting4.4998e-020.3818image
chr4:165074503-165079060:-THCAEERT_cells_regulatory_(Tregs)6.2605e-110.2858image
ENSG00000170088.12,TMEM192THCAEAGT_cells_regulatory_(Tregs)9.0025e-110.2835image
chr4:165074503-165079060:-THYMEERT_cells_CD4_memory_activated4.1836e-040.3264image
ENSG00000170088.12,TMEM192THYMEAGT_cells_CD4_memory_activated4.2607e-040.3260image
chr4:165074503-165079060:-UCECEERB_cells_memory6.9336e-030.2046image
ENSG00000170088.12,TMEM192UCECEAGB_cells_memory7.6201e-030.2022image
chr4:165074503-165079060:-UCSEERT_cells_follicular_helper1.2616e-02-0.3405image
ENSG00000170088.12,TMEM192UCSEAGT_cells_follicular_helper1.2616e-02-0.3405image
chr4:165074503-165079060:-UVMEERT_cells_CD4_memory_resting2.0383e-03-0.3530image
ENSG00000170088.12,TMEM192UVMEAGT_cells_CD4_memory_resting2.0383e-03-0.3530image


Top

6. Enriched editing regions and immune gene sets for TMEM192


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr4:165074503-165079060:-BLCAEER1.1706e-02image5.5155e-080.2760image
ENSG00000170088.12,TMEM192BLCAEAG1.1751e-02image5.4897e-080.2761image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr4:165074503-165079060:-BLCAEER4.8072e-050.20833.3245e-040.18432.8327e-040.18645.4265e-060.2324image
ENSG00000170088.12,TMEM192BLCAEAG4.7876e-050.20833.3226e-040.18442.7978e-040.18665.3006e-060.2326image
chr4:165074503-165079060:-BRCAEER4.0784e-100.19043.8874e-040.10873.0496e-040.11061.6254e-040.1155image
ENSG00000170088.12,TMEM192BRCAEAG3.5551e-100.19103.3946e-040.10982.7093e-040.11162.0184e-040.1139image
chr4:165074503-165079060:-LUADEER2.5573e-030.13683.6358e-030.13203.7790e-030.13144.1646e-020.0926image
ENSG00000170088.12,TMEM192LUADEAG2.5103e-030.13713.5936e-030.13213.7079e-030.13174.1622e-020.0926image
chr4:165074503-165079060:-SKCMEER2.2988e-02-0.10586.9174e-03-0.12551.4392e-02-0.11383.0468e-030.1376image
ENSG00000170088.12,TMEM192SKCMEAG2.2418e-02-0.10626.4867e-03-0.12651.3725e-02-0.11463.1054e-030.1373image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000170088.12,TMEM192ACCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.5462e-020.2769image
chr4:165074503-165079060:-ACCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.5406e-020.2770image
ENSG00000170088.12,TMEM192BLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.7656e-120.3535image
chr4:165074503-165079060:-BLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.7663e-120.3535image
ENSG00000170088.12,TMEM192BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.0957e-130.2254image
chr4:165074503-165079060:-BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER9.5755e-140.2259image
chr4:165074503-165079060:-CESCGSVA_HALLMARK_COMPLEMENTEER3.4338e-040.2195image
ENSG00000170088.12,TMEM192CESCGSVA_HALLMARK_COMPLEMENTEAG3.4338e-040.2195image
chr4:165074503-165079060:-CHOLGSVA_HALLMARK_MYC_TARGETS_V2EER2.8620e-020.3812image
ENSG00000170088.12,TMEM192CHOLGSVA_HALLMARK_MYC_TARGETS_V2EAG2.8620e-020.3812image
ENSG00000170088.12,TMEM192COADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.2205e-060.2897image
chr4:165074503-165079060:-COADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.2205e-060.2897image
ENSG00000170088.12,TMEM192DLBCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.0078e-020.3680image
chr4:165074503-165079060:-DLBCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.0078e-020.3680image
chr4:165074503-165079060:-ESCAGSVA_HALLMARK_HYPOXIAEER7.1675e-050.3124image
ENSG00000170088.12,TMEM192ESCAGSVA_HALLMARK_HYPOXIAEAG7.9543e-050.3106image
chr4:165071311-165072399:-ESCAGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.0936e-020.5558image
ENSG00000170088.12,TMEM192GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.8332e-040.2934image
chr4:165074503-165079060:-GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.8557e-040.2931image
ENSG00000170088.12,TMEM192HNSCGSVA_HALLMARK_SPERMATOGENESISEAG3.5505e-07-0.2504image
chr4:165074503-165079060:-HNSCGSVA_HALLMARK_SPERMATOGENESISEER3.5369e-07-0.2504image
ENSG00000170088.12,TMEM192KICHGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.8742e-03-0.3786image
chr4:165074503-165079060:-KICHGSVA_HALLMARK_APICAL_SURFACEEER1.5143e-03-0.3856image
ENSG00000170088.12,TMEM192KIRCGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.3903e-13-0.3655image
chr4:165074503-165079060:-KIRCGSVA_HALLMARK_PROTEIN_SECRETIONEER1.2904e-13-0.3660image
chr4:165074503-165079060:-KIRPGSVA_HALLMARK_PROTEIN_SECRETIONEER3.3650e-06-0.2704image
ENSG00000170088.12,TMEM192KIRPGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.1232e-06-0.2756image
chr4:165074503-165079060:-LGGGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.0615e-090.2582image
ENSG00000170088.12,TMEM192LGGGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG2.1919e-090.2578image
chr4:165074503-165079060:-LIHCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.4527e-050.2230image
ENSG00000170088.12,TMEM192LIHCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.5010e-050.2226image
chr4:165074503-165079060:-LUADGSVA_HALLMARK_BILE_ACID_METABOLISMEER5.9401e-05-0.1815image
ENSG00000170088.12,TMEM192LUADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG5.7250e-05-0.1818image
ENSG00000170088.12,TMEM192LUSCGSVA_HALLMARK_HEME_METABOLISMEAG6.8112e-06-0.2251image
chr4:165074503-165079060:-LUSCGSVA_HALLMARK_HEME_METABOLISMEER6.8112e-06-0.2251image
chr4:165074503-165079060:-MESOGSVA_HALLMARK_HEME_METABOLISMEER1.2868e-02-0.2753image
ENSG00000170088.12,TMEM192MESOGSVA_HALLMARK_HEME_METABOLISMEAG1.2868e-02-0.2753image
chr4:165074503-165079060:-OVGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER2.7099e-04-0.2156image
ENSG00000170088.12,TMEM192OVGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG2.9330e-04-0.2145image
chr4:165074503-165079060:-PAADGSVA_HALLMARK_PROTEIN_SECRETIONEER4.1190e-04-0.2727image
ENSG00000170088.12,TMEM192PAADGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.1190e-04-0.2727image
ENSG00000170088.12,TMEM192PCPGGSVA_HALLMARK_KRAS_SIGNALING_DNEAG4.3824e-040.2573image
chr4:165074503-165079060:-PCPGGSVA_HALLMARK_KRAS_SIGNALING_DNEER4.3286e-040.2575image
chr4:165071311-165072399:-PRADGSVA_HALLMARK_UV_RESPONSE_DNEER1.7565e-02-0.4453image
ENSG00000170088.12,TMEM192PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.6587e-15-0.3463image
chr4:165074503-165079060:-PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEER3.2960e-15-0.3428image
ENSG00000170088.12,TMEM192READGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.6572e-030.2781image
chr4:165074503-165079060:-READGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.6572e-030.2781image
chr4:165074503-165079060:-SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.3361e-060.3227image
ENSG00000170088.12,TMEM192SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.3361e-060.3227image
chr4:165074503-165079060:-SKCMGSVA_HALLMARK_PROTEIN_SECRETIONEER4.4677e-12-0.3147image
ENSG00000170088.12,TMEM192SKCMGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.5033e-12-0.3146image
chr4:165074503-165079060:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.2211e-050.2295image
chr4:165071311-165072399:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.1855e-020.3572image
ENSG00000170088.12,TMEM192STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.9424e-050.2311image
chr4:165074503-165079060:-TGCTGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER9.5738e-030.2428image
ENSG00000170088.12,TMEM192TGCTGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG9.5738e-030.2428image
ENSG00000170088.12,TMEM192THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.2657e-160.3573image
chr4:165074503-165079060:-THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.7978e-170.3630image
ENSG00000170088.12,TMEM192THYMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG4.7722e-050.3728image
chr4:165074503-165079060:-THYMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER4.4963e-050.3740image
ENSG00000170088.12,TMEM192UCECGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.1231e-04-0.2709image
chr4:165074503-165079060:-UCECGSVA_HALLMARK_PROTEIN_SECRETIONEER4.3345e-04-0.2647image
chr4:165074503-165079060:-UCSGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER3.7340e-02-0.2868image
ENSG00000170088.12,TMEM192UCSGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.7340e-02-0.2868image
ENSG00000170088.12,TMEM192UVMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.5782e-060.5249image
chr4:165074503-165079060:-UVMGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.5782e-060.5249image


Top

7. Enriched editing regions and drugs for TMEM192


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr4:165074503-165079060:-BLCAFH535EER1.4726e-110.3393image
ENSG00000170088.12,TMEM192BLCAFH535EAG1.4465e-110.3395image
ENSG00000170088.12,TMEM192BRCACCT007093EAG4.5502e-170.2539image
chr4:165071311-165072399:-BRCAFH535EER5.7946e-03-0.5567image
chr4:165074503-165079060:-BRCACCT007093EER6.2118e-170.2528image
chr4:165074503-165079060:-CESCCI.1040EER3.4611e-04-0.2194image
ENSG00000170088.12,TMEM192CESCCI.1040EAG3.4611e-04-0.2194image
chr4:165074503-165079060:-CHOLJNK.Inhibitor.VIIIEER1.5173e-02-0.4192image
ENSG00000170088.12,TMEM192CHOLJNK.Inhibitor.VIIIEAG1.5173e-02-0.4192image
chr4:165074503-165079060:-COADGefitinibEER7.3097e-06-0.2751image
ENSG00000170088.12,TMEM192COADGefitinibEAG7.3097e-06-0.2751image
ENSG00000170088.12,TMEM192DLBCDoxorubicinEAG1.9772e-020.3354image
chr4:165074503-165079060:-DLBCDoxorubicinEER1.9772e-020.3354image
ENSG00000170088.12,TMEM192ESCACGP.60474EAG3.1915e-04-0.2845image
chr4:165071311-165072399:-ESCAGSK.650394EER1.4401e-020.5380image
chr4:165074503-165079060:-ESCACGP.60474EER2.3923e-04-0.2901image
chr4:165074503-165079060:-GBMMG.132EER4.9987e-03-0.2223image
ENSG00000170088.12,TMEM192GBMMG.132EAG5.1184e-03-0.2217image
chr4:165074503-165079060:-HNSCErlotinibEER4.3455e-08-0.2692image
ENSG00000170088.12,TMEM192HNSCErlotinibEAG4.2735e-08-0.2694image
ENSG00000170088.12,TMEM192KICHBIRB.0796EAG1.4668e-06-0.5567image
chr4:165074503-165079060:-KICHBIRB.0796EER8.7509e-07-0.5664image
chr4:165074503-165079060:-KIRCCamptothecinEER8.2082e-15-0.3823image
ENSG00000170088.12,TMEM192KIRCCamptothecinEAG1.3133e-14-0.3796image
chr4:165074503-165079060:-KIRPAZD6482EER5.4254e-070.2906image
ENSG00000170088.12,TMEM192KIRPAZD6482EAG2.6622e-070.2981image
ENSG00000170088.12,TMEM192LAMLBMS.708163EAG9.5941e-04-0.3667image
chr4:165074503-165079060:-LAMLBMS.708163EER9.2426e-04-0.3678image
ENSG00000170088.12,TMEM192LGGKU.55933EAG1.6126e-13-0.3154image
chr4:165074503-165079060:-LGGKU.55933EER1.4708e-13-0.3159image
chr4:165074503-165079060:-LIHCKIN001.135EER1.4291e-060.2472image
ENSG00000170088.12,TMEM192LIHCKIN001.135EAG1.4765e-060.2469image
ENSG00000170088.12,TMEM192LUADGW843682XEAG1.2003e-08-0.2554image
chr4:165074503-165079060:-LUADGW843682XEER1.2332e-08-0.2552image
chr4:165074503-165079060:-LUSCBI.D1870EER4.6419e-05-0.2042image
ENSG00000170088.12,TMEM192LUSCBI.D1870EAG4.6419e-05-0.2042image
ENSG00000170088.12,TMEM192MESOBX.795EAG8.7910e-03-0.2894image
chr4:165074503-165079060:-MESOBX.795EER8.7910e-03-0.2894image
chr4:165071311-165072399:-OVAG.014699EER1.6228e-02-0.3875image
ENSG00000170088.12,TMEM192OVEmbelinEAG5.7476e-070.2930image
chr4:165074503-165079060:-OVEmbelinEER4.0991e-070.2966image
chr4:165074503-165079060:-PAADBIBW2992EER1.0894e-03-0.2528image
ENSG00000170088.12,TMEM192PAADBIBW2992EAG1.0894e-03-0.2528image
ENSG00000170088.12,TMEM192PCPGFTI.277EAG1.1569e-030.2384image
chr4:165074503-165079060:-PCPGFTI.277EER1.1888e-030.2378image
ENSG00000170088.12,TMEM192PRADBortezomibEAG1.9718e-14-0.3336image
chr4:165074503-165079060:-PRADBortezomibEER1.9278e-14-0.3337image
chr4:165071311-165072399:-PRADBX.795EER1.6801e-040.6525image
chr4:165074503-165079060:-READBMS.754807EER8.4307e-03-0.2702image
ENSG00000170088.12,TMEM192READBMS.754807EAG8.4307e-03-0.2702image
ENSG00000170088.12,TMEM192SARCFH535EAG7.7639e-060.2997image
chr4:165074503-165079060:-SARCFH535EER7.7639e-060.2997image
chr4:165074503-165079060:-SKCMCGP.60474EER6.9245e-13-0.3258image
ENSG00000170088.12,TMEM192SKCMCGP.60474EAG7.2058e-13-0.3256image
chr4:165074503-165079060:-STADGW843682XEER4.1042e-04-0.1920image
ENSG00000170088.12,TMEM192STADGW843682XEAG3.7512e-04-0.1932image
chr4:165074503-165079060:-TGCTBMS.754807EER7.8842e-040.3114image
ENSG00000170088.12,TMEM192TGCTBMS.754807EAG7.8842e-040.3114image
chr4:165071311-165072399:-THCABryostatin.1EER3.0351e-020.4098image
chr4:165074503-165079060:-THCAEmbelinEER2.0285e-310.4873image
ENSG00000170088.12,TMEM192THCAEmbelinEAG4.5195e-310.4848image
ENSG00000170088.12,TMEM192THYMFH535EAG4.8606e-060.4150image
chr4:165074503-165079060:-THYMFH535EER4.8809e-060.4150image
ENSG00000170088.12,TMEM192UCECLenalidomideEAG3.0551e-06-0.3463image
chr4:165074503-165079060:-UCECLenalidomideEER4.6804e-06-0.3401image
chr4:165074503-165079060:-UCSMetforminEER3.3165e-03-0.3962image
ENSG00000170088.12,TMEM192UCSMetforminEAG3.3165e-03-0.3962image
chr4:165074503-165079060:-UVMGNF.2EER6.4473e-08-0.5792image
ENSG00000170088.12,TMEM192UVMGNF.2EAG6.4473e-08-0.5792image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType